Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients

Shun F. Yang, Yih Shou Hsieh, Chiao L. Lin, Nan Yung Hsu, Hui Ling Chiou, Fen P. Chou, Shu Chen Chu

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Background: The involvements of matrix metalloproteinase-9 (MMP-9) and urokinase plasminogen activator (uPA) in the pathogenesis of various types of lung cancers have been established. The aim of the present study was to determine the concentrations of MMP-9 and uPA in the plasma of nonsmall cell lung cancer (NSCLC) patients. Methods: Gelatin zymography and ELISA were used to measure MMP-9 and uPA concentrations, respectively, in 90 NSCLC patients and 50 control subjects. Results: Compared with that of control subjects, MMP-9 and uPA levels were significantly higher in the plasma of NSCLC patients (P<0.001 and P<0.01, respectively). Further statistical analysis for clinic pathological parameters revealed that MMP-9 and uPA levels were significantly increased in patients with metastasis (P<0.01 and P<0.05, respectively). Furthermore, the MMP-9 level was significantly different between smokers and nonsmokers (P<0.05) while uPA levels varied between histological types (P<0.05). Conclusions: Plasma MMP-9 and uPA might play an important role in the metastasis of NSCLC by involvement in the processes of invasion and metastasis. © 2004 Elsevier B.V. All rights reserved.

Original languageEnglish
Pages (from-to)91-99
Number of pages9
JournalClinica Chimica Acta
Volume354
Issue number1-2
DOIs
Publication statusPublished - Apr 2005
Externally publishedYes

Fingerprint

Plasminogen Activators
Matrix Metalloproteinase 9
Urokinase-Type Plasminogen Activator
Non-Small Cell Lung Carcinoma
Cells
Plasmas
Neoplasm Metastasis
Plasma Cells
Gelatin
Lung Neoplasms
Statistical methods
Enzyme-Linked Immunosorbent Assay

Keywords

  • Matrix metalloproteinase-9
  • Nonsmall cell lung cancer
  • Urokinase plasminogen activator

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. / Yang, Shun F.; Hsieh, Yih Shou; Lin, Chiao L.; Hsu, Nan Yung; Chiou, Hui Ling; Chou, Fen P.; Chu, Shu Chen.

In: Clinica Chimica Acta, Vol. 354, No. 1-2, 04.2005, p. 91-99.

Research output: Contribution to journalArticle

Yang, Shun F. ; Hsieh, Yih Shou ; Lin, Chiao L. ; Hsu, Nan Yung ; Chiou, Hui Ling ; Chou, Fen P. ; Chu, Shu Chen. / Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. In: Clinica Chimica Acta. 2005 ; Vol. 354, No. 1-2. pp. 91-99.
@article{c651e17dcbf94fe39349a43a1e11d90d,
title = "Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients",
abstract = "Background: The involvements of matrix metalloproteinase-9 (MMP-9) and urokinase plasminogen activator (uPA) in the pathogenesis of various types of lung cancers have been established. The aim of the present study was to determine the concentrations of MMP-9 and uPA in the plasma of nonsmall cell lung cancer (NSCLC) patients. Methods: Gelatin zymography and ELISA were used to measure MMP-9 and uPA concentrations, respectively, in 90 NSCLC patients and 50 control subjects. Results: Compared with that of control subjects, MMP-9 and uPA levels were significantly higher in the plasma of NSCLC patients (P<0.001 and P<0.01, respectively). Further statistical analysis for clinic pathological parameters revealed that MMP-9 and uPA levels were significantly increased in patients with metastasis (P<0.01 and P<0.05, respectively). Furthermore, the MMP-9 level was significantly different between smokers and nonsmokers (P<0.05) while uPA levels varied between histological types (P<0.05). Conclusions: Plasma MMP-9 and uPA might play an important role in the metastasis of NSCLC by involvement in the processes of invasion and metastasis. {\circledC} 2004 Elsevier B.V. All rights reserved.",
keywords = "Matrix metalloproteinase-9, Nonsmall cell lung cancer, Urokinase plasminogen activator",
author = "Yang, {Shun F.} and Hsieh, {Yih Shou} and Lin, {Chiao L.} and Hsu, {Nan Yung} and Chiou, {Hui Ling} and Chou, {Fen P.} and Chu, {Shu Chen}",
year = "2005",
month = "4",
doi = "10.1016/j.cccn.2004.11.011",
language = "English",
volume = "354",
pages = "91--99",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients

AU - Yang, Shun F.

AU - Hsieh, Yih Shou

AU - Lin, Chiao L.

AU - Hsu, Nan Yung

AU - Chiou, Hui Ling

AU - Chou, Fen P.

AU - Chu, Shu Chen

PY - 2005/4

Y1 - 2005/4

N2 - Background: The involvements of matrix metalloproteinase-9 (MMP-9) and urokinase plasminogen activator (uPA) in the pathogenesis of various types of lung cancers have been established. The aim of the present study was to determine the concentrations of MMP-9 and uPA in the plasma of nonsmall cell lung cancer (NSCLC) patients. Methods: Gelatin zymography and ELISA were used to measure MMP-9 and uPA concentrations, respectively, in 90 NSCLC patients and 50 control subjects. Results: Compared with that of control subjects, MMP-9 and uPA levels were significantly higher in the plasma of NSCLC patients (P<0.001 and P<0.01, respectively). Further statistical analysis for clinic pathological parameters revealed that MMP-9 and uPA levels were significantly increased in patients with metastasis (P<0.01 and P<0.05, respectively). Furthermore, the MMP-9 level was significantly different between smokers and nonsmokers (P<0.05) while uPA levels varied between histological types (P<0.05). Conclusions: Plasma MMP-9 and uPA might play an important role in the metastasis of NSCLC by involvement in the processes of invasion and metastasis. © 2004 Elsevier B.V. All rights reserved.

AB - Background: The involvements of matrix metalloproteinase-9 (MMP-9) and urokinase plasminogen activator (uPA) in the pathogenesis of various types of lung cancers have been established. The aim of the present study was to determine the concentrations of MMP-9 and uPA in the plasma of nonsmall cell lung cancer (NSCLC) patients. Methods: Gelatin zymography and ELISA were used to measure MMP-9 and uPA concentrations, respectively, in 90 NSCLC patients and 50 control subjects. Results: Compared with that of control subjects, MMP-9 and uPA levels were significantly higher in the plasma of NSCLC patients (P<0.001 and P<0.01, respectively). Further statistical analysis for clinic pathological parameters revealed that MMP-9 and uPA levels were significantly increased in patients with metastasis (P<0.01 and P<0.05, respectively). Furthermore, the MMP-9 level was significantly different between smokers and nonsmokers (P<0.05) while uPA levels varied between histological types (P<0.05). Conclusions: Plasma MMP-9 and uPA might play an important role in the metastasis of NSCLC by involvement in the processes of invasion and metastasis. © 2004 Elsevier B.V. All rights reserved.

KW - Matrix metalloproteinase-9

KW - Nonsmall cell lung cancer

KW - Urokinase plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=14644400398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644400398&partnerID=8YFLogxK

U2 - 10.1016/j.cccn.2004.11.011

DO - 10.1016/j.cccn.2004.11.011

M3 - Article

C2 - 15748604

AN - SCOPUS:14644400398

VL - 354

SP - 91

EP - 99

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -